Michaela Defrancesco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michaela Defrancesco has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
Josef Marksteiner
Department of Psychiatry and Psychotherapy A, Hall State Hospital
14 shared publicationsGeorg Kemmler
Department of Psychiatry, Psychotherapy and Psychosomatics, Division of Psychiatry I, Medical University of Innsbruck, Innsbruck, Austria
10 shared publicationsEberhard A. Deisenhammer
Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Medical University of Innsbruck, Austria
8 shared publicationsAlex Hofer
Medical University of Innsbruck
7 shared publicationsHartmann Hinterhuber
Universitätsklinik für Psychiatrie I, Department Psychiatrie, Psychotherapie und Psychosomatik, Medizinische Universität Innsbruck, Innsbruck, Österreich
7 shared publicationsBurak Doganyigit
Medical University of Innsbruck
4 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Wiley in Aging Cell
- Vol. 25 (11)
Long‐Term Post‐Mitotic Culture of Human Fibroblasts Recapitulates and Accelerates Features of In Vivo Aging and Enables Dynamic Testing of Anti‐Aging Compounds
Biological aging drives cellular dysfunction and human disease, yet studying human aging dynamics remains challenging due to limited experimental platforms. Here we show that long‐term post‐mitotic culture of human fibroblasts recapitulates and accelerates features of in vivo aging. Longitudinal paired transcriptomic and epigenetic analyses of four female fibroblast lines revealed that in vitro aging reflects key signatures of in vivo primary fibroblast aging. Direct neuronal conversion of in vitro‐aged fibroblasts preserved biological age, enabling pseudo‐longitudinal modeling of neuronal aging through direct reprogramming. Single‐cell transcriptomics of in vitro‐aging fibroblasts revealed a time‐dependent increase in age‐heterogeneity, consistent with the previously reported age‐associated heterogeneity driven by the variable loss of transcriptional programs in vivo. Using this accelerated aging platform, we evaluated anti‐aging compounds: Metformin broadly attenuated transcriptomic and epigenetic aging, while Rapamycin showed limited efficacy. These findings align with pre‐clinical evidence, providing a platform to evaluate and predict therapeutic anti‐aging compound efficacy at molecular resolution. This system advances our understanding of aging mechanisms and facilitates the development of interventions against age‐related diseases.
- 1 November 2026
- Published by Wiley in Aging Cell
- Vol. 25 (11)
Open AccessLong‐Term Post‐Mitotic Culture of Human Fibroblasts Recapitulates and Accelerates Features of In Vivo Aging and Enables Dynamic Testing of Anti‐Aging Compounds
Biological aging drives cellular dysfunction and human disease, yet studying human aging dynamics remains challenging due to limited experimental platforms. Here we show that long‐term post‐mitotic culture of human fibroblasts recapitulates and accelerates features of in vivo aging. Longitudinal paired transcriptomic and epigenetic analyses of four female fibroblast lines revealed that in vitro aging reflects key signatures of in vivo primary fibroblast aging. Direct neuronal conversion of in vitro‐aged fibroblasts preserved biological age, enabling pseudo‐longitudinal modeling of neuronal aging through direct reprogramming. Single‐cell transcriptomics of in vitro‐aging fibroblasts revealed a time‐dependent increase in age‐heterogeneity, consistent with the previously reported age‐associated heterogeneity driven by the variable loss of transcriptional programs in vivo. Using this accelerated aging platform, we evaluated anti‐aging compounds: Metformin broadly attenuated transcriptomic and epigenetic aging, while Rapamycin showed limited efficacy. These findings align with pre‐clinical evidence, providing a platform to evaluate and predict therapeutic anti‐aging compound efficacy at molecular resolution. This system advances our understanding of aging mechanisms and facilitates the development of interventions against age‐related diseases.
- Open Access
- 11 July 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 113 (1) , 291-301
Multidomain cognitive impairment, along with comorbidities and psychiatric hospitalizations, shorten survival time of patients with Alzheimer's disease dementia: A long term, naturalistic follow-up study
Background: The survival time following an initial Alzheimer's disease dementia (ADD) diagnosis is influenced by various demographic, cognitive and clinical factors. Cognitive clusters are more detailed than individual cognitive measures, but they are rarely used as predictors in survival analyses. Objective: We conducted a long-term retrospective study following patients from the time of their initial ADD diagnosis until their death. Cognitive clusters as well as clinical data were assessed as predictors of survival time. Methods: We used hierarchical clustering to identify cognitive clusters based on the results of neuropsychological examinations (CERAD-Plus). We fitted a Cox regression model with cognitive clusters and clinical covariates (e.g., age, sex, Mini-Mental State Examination [MMSE] score, annual rate of hospitalizations, and pre-existing diseases) to predict survival time. Results: Data from 202 patients (mean age = 77.79 ± 5.35 years; mean survival time 74.04 ± 41.03 months) were analyzed. Two cognitive clusters were identified: the amnestic cluster (AC, N = 89) and the mixed cluster (MC, N = 80). The Cox regression models identified the following variables as most predictive of shorter survival times: higher age (HR = 1.04) and lower MMSE score at baseline (HR = 0.92), pre-diagnosed atrial fibrillation (HR = 2.06) and delirium (HR = 3.13), and a higher annual rate of psychiatric (HR = 4.84) and somatic (HR = 1.67) hospitalizations. Patients in the MC had a shorter survival time than those in the AC group (HR = 1.45). Conclusions: This study provides evidence that a detailed analysis of neuropsychological profiles at the time of ADD diagnosis can predict disease progression. Preventing psychiatric hospitalizations, especially, could positively influence the survival of ADD patients.
- 11 July 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 113 (1) , 291-301
Open AccessMultidomain cognitive impairment, along with comorbidities and psychiatric hospitalizations, shorten survival time of patients with Alzheimer's disease dementia: A long term, naturalistic follow-up study
Background: The survival time following an initial Alzheimer's disease dementia (ADD) diagnosis is influenced by various demographic, cognitive and clinical factors. Cognitive clusters are more detailed than individual cognitive measures, but they are rarely used as predictors in survival analyses. Objective: We conducted a long-term retrospective study following patients from the time of their initial ADD diagnosis until their death. Cognitive clusters as well as clinical data were assessed as predictors of survival time. Methods: We used hierarchical clustering to identify cognitive clusters based on the results of neuropsychological examinations (CERAD-Plus). We fitted a Cox regression model with cognitive clusters and clinical covariates (e.g., age, sex, Mini-Mental State Examination [MMSE] score, annual rate of hospitalizations, and pre-existing diseases) to predict survival time. Results: Data from 202 patients (mean age = 77.79 ± 5.35 years; mean survival time 74.04 ± 41.03 months) were analyzed. Two cognitive clusters were identified: the amnestic cluster (AC, N = 89) and the mixed cluster (MC, N = 80). The Cox regression models identified the following variables as most predictive of shorter survival times: higher age (HR = 1.04) and lower MMSE score at baseline (HR = 0.92), pre-diagnosed atrial fibrillation (HR = 2.06) and delirium (HR = 3.13), and a higher annual rate of psychiatric (HR = 4.84) and somatic (HR = 1.67) hospitalizations. Patients in the MC had a shorter survival time than those in the AC group (HR = 1.45). Conclusions: This study provides evidence that a detailed analysis of neuropsychological profiles at the time of ADD diagnosis can predict disease progression. Preventing psychiatric hospitalizations, especially, could positively influence the survival of ADD patients.
- Open Access
- 13 February 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1714247
Plasma phospho-tau 217 outperforms plasma phospho-tau 181 analyzed with Lumipulse in detecting Alzheimer’s dementia in a real-world memory clinic population
Introduction: We need easy-to-use, valid biomarkers for diagnosing Alzheimer’s disease (AD). Blood biomarkers are a promising option, especially as there is a good correlation with beta-amyloid and tau biomarkers measured by positron emission tomography or in the cerebrospinal fluid. We investigated the added value of measuring these markers in the blood of patients who have already been diagnosed, and how cut-off values can be set in clinical routine. Methods: Plasma pTau 181 and pTau 217 levels were analyzed using Lumipulse G600II in 132 memory clinic outpatients with different forms of dementia and in 43 cognitively intact controls (CIC). Linear discriminant analysis was used to determine the diagnostic accuracy of pTau 181, pTau 217, and the pTau 217/181 ratio in plasma. The Youden index (YI) was calculated to determine optimal cut-points. Results: The diagnostic performance of pTau levels to distinguish between dementia patients and CIC yielded an AUC of 0.724 (95% CI: 0.635–0.813) with a cut point (YI) of 1.46 pg/mL for pTau 181 and an AUC of 0.845 (95% CI: 0.763–0.927) with a cut point (YI) of 0.23 pg/mL for pTau 217. The pTau217/181 ratio showed slightly better discriminatory performance (AUC of 0.858 [95% CI: 0.769–0.946]) at a cut point (YI) of 0.18. Discussion: We suggest that the combined use of pTau217 and pTau181 as a ratio may serve as a valuable method to differentiate AD from non-AD dementia and from cognitively healthy individuals. However, plasma pTau217 outperforms pTau181 and the ratio due to its greater stability and marginally higher sensitivity compared to the 217/181 ratio. Plasma pTau217 levels above the cut-off point could indicate the need for further investigation of biomarkers.
- 13 February 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1714247
Open AccessPlasma phospho-tau 217 outperforms plasma phospho-tau 181 analyzed with Lumipulse in detecting Alzheimer’s dementia in a real-world memory clinic population
Introduction: We need easy-to-use, valid biomarkers for diagnosing Alzheimer’s disease (AD). Blood biomarkers are a promising option, especially as there is a good correlation with beta-amyloid and tau biomarkers measured by positron emission tomography or in the cerebrospinal fluid. We investigated the added value of measuring these markers in the blood of patients who have already been diagnosed, and how cut-off values can be set in clinical routine. Methods: Plasma pTau 181 and pTau 217 levels were analyzed using Lumipulse G600II in 132 memory clinic outpatients with different forms of dementia and in 43 cognitively intact controls (CIC). Linear discriminant analysis was used to determine the diagnostic accuracy of pTau 181, pTau 217, and the pTau 217/181 ratio in plasma. The Youden index (YI) was calculated to determine optimal cut-points. Results: The diagnostic performance of pTau levels to distinguish between dementia patients and CIC yielded an AUC of 0.724 (95% CI: 0.635–0.813) with a cut point (YI) of 1.46 pg/mL for pTau 181 and an AUC of 0.845 (95% CI: 0.763–0.927) with a cut point (YI) of 0.23 pg/mL for pTau 217. The pTau217/181 ratio showed slightly better discriminatory performance (AUC of 0.858 [95% CI: 0.769–0.946]) at a cut point (YI) of 0.18. Discussion: We suggest that the combined use of pTau217 and pTau181 as a ratio may serve as a valuable method to differentiate AD from non-AD dementia and from cognitively healthy individuals. However, plasma pTau217 outperforms pTau181 and the ratio due to its greater stability and marginally higher sensitivity compared to the 217/181 ratio. Plasma pTau217 levels above the cut-off point could indicate the need for further investigation of biomarkers.
- Open Access
- 15 January 2026
- Published by Springer Nature in neuropsychiatrie
- p. 1-12
Geringe Pflegebelastung und hohe Selbstwirksamkeit sind wesentlich um pflegende Angehörige gut auf die Pflege von Menschen mit Demenz vorzubereiten – Ergebnisse des TeleCareHub Projektes
Zusammenfassung: Hintergrund: Die Pflege und Betreuung von Menschen mit Demenz (MmD) wird überwiegend von informell Pflegenden und Betreuenden (iPuB) übernommen. Ein hohes Maß an Vorbereitet-sein („preparedness“) auf die Pflegetätigkeiten verbessert die Versorgung von MmD und vermindert die Pflegebelastung. Die Entwicklung von Unterstützungs- und Informationsangeboten, um die „preparedness“ zu steigern, ist ein wesentliches Ziel des vom FFG-geförderten Projekts TeleCareHub. Methodik: In dieser multizentrischen Querschnittsuntersuchung wurden Daten von iPuB mit folgenden Fragebögen erhoben: Allgemeine Selbstwirksamkeits-Kurzskala (ASKU-3), Affinity for Technology Interaction Scale (ATI-8), Zarit Burden Interview (ZBI-7), Loneliness Scale (UCLA-3), Patient Health Questionnaire (PHQ-9), Scale for the Quality of the Current Relationship in Caregiving (SQCRC-14) und die Preparedness for Caregiving Scale (PCS-8). Die Datenanalyse erfolgte mittels Korrelationsanalysen, linearen Regressionsanalysen (einschließlich Mediations- und Moderationsmodellen) sowie Varianzanalysen. Ergebnisse: Es wurden Daten von 308 iPuB (76 % weiblich, PCS-8: 20,8 ± 6,4) analysiert. Die Selbstwirksamkeit (ASKU-3) und Beziehungsqualität (SQCRC-14) korrelierten signifikant positiv mit der „preparedness“ (PCS-8), wohingegen die Pflegebelastung (ZBI-7), Einsamkeit (UCLA-3) und Depressivität (PHQ-9) negative mit der PCS‑8 korrelierten. Bei nicht belasteten iPuB (ZBI-7 < 11), aber nicht bei belasteten iPuB, waren ein niederer ZBI‑7 Wert sowie eine geringe Pflegedauer prädiktiv für eine hohe „preparedness“ (β = −0,318; SE = 0,077; p < 0,001). Ergebnisse von SQCRC-14, ASKU‑3 und PHQ‑9 zeigten signifikant modulierende Effekte auf die PCS‑8. Schlussfolgerungen: Die Ergebnisse unterstreichen den Einfluss multipler persönlicher Faktoren von iPuB auf das Gefühl, auf die Pflegetätigkeit vorbereitet zu sein. Besonders bei noch nicht belasteten iPuB könnten Interventionen sowie digitale Angebote zur Stärkung der Selbstwirksamkeit und Verminderung von Depressivität, die „preparedness“ verbessern.
- 15 January 2026
- Published by Springer Nature in neuropsychiatrie
- p. 1-12
Open AccessGeringe Pflegebelastung und hohe Selbstwirksamkeit sind wesentlich um pflegende Angehörige gut auf die Pflege von Menschen mit Demenz vorzubereiten – Ergebnisse des TeleCareHub Projektes
Zusammenfassung: Hintergrund: Die Pflege und Betreuung von Menschen mit Demenz (MmD) wird überwiegend von informell Pflegenden und Betreuenden (iPuB) übernommen. Ein hohes Maß an Vorbereitet-sein („preparedness“) auf die Pflegetätigkeiten verbessert die Versorgung von MmD und vermindert die Pflegebelastung. Die Entwicklung von Unterstützungs- und Informationsangeboten, um die „preparedness“ zu steigern, ist ein wesentliches Ziel des vom FFG-geförderten Projekts TeleCareHub. Methodik: In dieser multizentrischen Querschnittsuntersuchung wurden Daten von iPuB mit folgenden Fragebögen erhoben: Allgemeine Selbstwirksamkeits-Kurzskala (ASKU-3), Affinity for Technology Interaction Scale (ATI-8), Zarit Burden Interview (ZBI-7), Loneliness Scale (UCLA-3), Patient Health Questionnaire (PHQ-9), Scale for the Quality of the Current Relationship in Caregiving (SQCRC-14) und die Preparedness for Caregiving Scale (PCS-8). Die Datenanalyse erfolgte mittels Korrelationsanalysen, linearen Regressionsanalysen (einschließlich Mediations- und Moderationsmodellen) sowie Varianzanalysen. Ergebnisse: Es wurden Daten von 308 iPuB (76 % weiblich, PCS-8: 20,8 ± 6,4) analysiert. Die Selbstwirksamkeit (ASKU-3) und Beziehungsqualität (SQCRC-14) korrelierten signifikant positiv mit der „preparedness“ (PCS-8), wohingegen die Pflegebelastung (ZBI-7), Einsamkeit (UCLA-3) und Depressivität (PHQ-9) negative mit der PCS‑8 korrelierten. Bei nicht belasteten iPuB (ZBI-7 < 11), aber nicht bei belasteten iPuB, waren ein niederer ZBI‑7 Wert sowie eine geringe Pflegedauer prädiktiv für eine hohe „preparedness“ (β = −0,318; SE = 0,077; p < 0,001). Ergebnisse von SQCRC-14, ASKU‑3 und PHQ‑9 zeigten signifikant modulierende Effekte auf die PCS‑8. Schlussfolgerungen: Die Ergebnisse unterstreichen den Einfluss multipler persönlicher Faktoren von iPuB auf das Gefühl, auf die Pflegetätigkeit vorbereitet zu sein. Besonders bei noch nicht belasteten iPuB könnten Interventionen sowie digitale Angebote zur Stärkung der Selbstwirksamkeit und Verminderung von Depressivität, die „preparedness“ verbessern.
- Open Access
- 6 December 2024
- Published by Elsevier in International Journal of Clinical and Health Psychology
- Vol. 24 (4) , 100530
Psychological telephone triage system for outpatient memory clinics - a way for adaptation to new challenges of increasing dementia prevalence and new treatment options?
- 6 December 2024
- Published by Elsevier in International Journal of Clinical and Health Psychology
- Vol. 24 (4) , 100530
Open AccessPsychological telephone triage system for outpatient memory clinics - a way for adaptation to new challenges of increasing dementia prevalence and new treatment options?
- Open Access
- 19 November 2024
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 15, 1485620
Temporal atrophy together with verbal encoding impairment is highly predictive for cognitive decline in typical Alzheimer’s dementia – a retrospective follow-up study
Introduction: The increasing prevalence of Alzheimer’s disease (AD) has created an urgent need for rapid and cost-effective methods to diagnose and monitor people at all stages of the disease. Progressive memory impairment and hippocampal atrophy are key features of the most common so-called typical variant of AD. However, studies evaluating detailed cognitive measures combined with region of interest (ROI)-based imaging markers of progression over the long term in the AD dementia (ADD) stage are rare.Method: We conducted a retrospective longitudinal follow-up study in patients with mild to moderate ADD (aged 60-92 years). They underwent magnetic resonance imaging (MRI; 3 Tesla, MPRAGE) as well as clinical and neuropsychological examination (Consortium to Establish a Registry for Alzheimer’s Disease [CERAD] -Plus test battery) at baseline and at least one follow-up visit. ROI-based brain structural analysis of baseline MRIs was performed using the Computational Anatomy Toolbox (CAT) 12. Clinical dementia progression (progression index [PI]) was measured by the annual decline in the Mini Mental State Examination (MMSE) scores. MRI, demographic, and neuropsychological data were included in univariate and multiple linear regression models to predict the PI.Results: 104 ADD patients (age 63 to 90 years, 73% female, mean MMSE score 22.63 ± 3.77, mean follow-up 4.27 ± 2.15 years) and 32 age- and gender-matched cognitively intact controls were included. The pattern of gray matter (GM) atrophy and the cognitive profile were consistent with the amnestic/typical variant of ADD in all patients. Deficits in word list learning together with temporal lobe GM atrophy had the highest predictive value for rapid cognitive decline in the multiple linear regression model, accounting for 25.4% of the PI variance.Discussion: Our results show that temporal atrophy together with deficits in the encoding of verbal material, rather than in immediate or delayed recall, is highly predictive for rapid cognitive decline in patients with mild to moderate amnestic/typical ADD. These findings point to the relevance of combining detailed cognitive and automated structural imaging analyses to predict clinical progression in patients with ADD.
- 19 November 2024
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 15, 1485620
Open AccessTemporal atrophy together with verbal encoding impairment is highly predictive for cognitive decline in typical Alzheimer’s dementia – a retrospective follow-up study
Introduction: The increasing prevalence of Alzheimer’s disease (AD) has created an urgent need for rapid and cost-effective methods to diagnose and monitor people at all stages of the disease. Progressive memory impairment and hippocampal atrophy are key features of the most common so-called typical variant of AD. However, studies evaluating detailed cognitive measures combined with region of interest (ROI)-based imaging markers of progression over the long term in the AD dementia (ADD) stage are rare.Method: We conducted a retrospective longitudinal follow-up study in patients with mild to moderate ADD (aged 60-92 years). They underwent magnetic resonance imaging (MRI; 3 Tesla, MPRAGE) as well as clinical and neuropsychological examination (Consortium to Establish a Registry for Alzheimer’s Disease [CERAD] -Plus test battery) at baseline and at least one follow-up visit. ROI-based brain structural analysis of baseline MRIs was performed using the Computational Anatomy Toolbox (CAT) 12. Clinical dementia progression (progression index [PI]) was measured by the annual decline in the Mini Mental State Examination (MMSE) scores. MRI, demographic, and neuropsychological data were included in univariate and multiple linear regression models to predict the PI.Results: 104 ADD patients (age 63 to 90 years, 73% female, mean MMSE score 22.63 ± 3.77, mean follow-up 4.27 ± 2.15 years) and 32 age- and gender-matched cognitively intact controls were included. The pattern of gray matter (GM) atrophy and the cognitive profile were consistent with the amnestic/typical variant of ADD in all patients. Deficits in word list learning together with temporal lobe GM atrophy had the highest predictive value for rapid cognitive decline in the multiple linear regression model, accounting for 25.4% of the PI variance.Discussion: Our results show that temporal atrophy together with deficits in the encoding of verbal material, rather than in immediate or delayed recall, is highly predictive for rapid cognitive decline in patients with mild to moderate amnestic/typical ADD. These findings point to the relevance of combining detailed cognitive and automated structural imaging analyses to predict clinical progression in patients with ADD.
- 30 September 2024
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 136, 111157
Combined cognitive assessment and automated MRI volumetry improves the diagnostic accuracy of detecting MCI due to Alzheimer's disease
- 30 September 2024
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 136, 111157
Combined cognitive assessment and automated MRI volumetry improves the diagnostic accuracy of detecting MCI due to Alzheimer's disease
- Open Access
- 23 September 2024
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 10 (5) , e160
Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic population
Background: Pharmacological treatment options for patients with dementia owing to Alzheimer's disease are limited to symptomatic therapy. Recently, the US Food and Drug Administration approved the monoclonal antibody lecanemab for the treatment of amyloid-positive patients with mild cognitive impairment (MCI) and early Alzheimer´s dementia. European approval is expected in 2024. Data on the applicability and eligibility for treatment with anti-amyloid monoclonal antibodies outside of a study population are lacking. Aims: This study examined eligibility criteria for lecanemab in a real-world memory clinic population between 1 January 2022 and 31 July 2023. Method: We conducted a retrospective, single-centre study applying the clinical trial eligibility criteria for lecanemab to out-patients of a specialised psychiatric memory clinic. Eligibility for anti-amyloid treatment was assessed following the phase 3 inclusion and exclusion criteria and the published recommendations for lecanemab. Results: The study population consisted of 587 out-patients. Two-thirds were diagnosed with Alzheimer's disease (probable or possible Alzheimer's disease dementia in 43.6% of cases, n = 256) or MCI (23%, n = 135), and 33.4% (n = 196) were diagnosed with dementia or neurocognitive disorder owing to another aetiology. Applying all lecanemab eligibility criteria, 11 (4.3%) patients with dementia and two (1.5%) patients with MCI would have been eligible for treatment with this compound, whereas 13 dementia (5.1%) and 14 (10.4%) MCI patients met clinical inclusion criteria, but had no available amyloid status. Conclusions: Even in a memory clinic with a good infrastructure and sufficient facilities for dementia diagnostics, most patients do not meet the eligibility criteria for treatment with lecanemab.
- 23 September 2024
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 10 (5) , e160
Open AccessInvestigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic population
Background: Pharmacological treatment options for patients with dementia owing to Alzheimer's disease are limited to symptomatic therapy. Recently, the US Food and Drug Administration approved the monoclonal antibody lecanemab for the treatment of amyloid-positive patients with mild cognitive impairment (MCI) and early Alzheimer´s dementia. European approval is expected in 2024. Data on the applicability and eligibility for treatment with anti-amyloid monoclonal antibodies outside of a study population are lacking. Aims: This study examined eligibility criteria for lecanemab in a real-world memory clinic population between 1 January 2022 and 31 July 2023. Method: We conducted a retrospective, single-centre study applying the clinical trial eligibility criteria for lecanemab to out-patients of a specialised psychiatric memory clinic. Eligibility for anti-amyloid treatment was assessed following the phase 3 inclusion and exclusion criteria and the published recommendations for lecanemab. Results: The study population consisted of 587 out-patients. Two-thirds were diagnosed with Alzheimer's disease (probable or possible Alzheimer's disease dementia in 43.6% of cases, n = 256) or MCI (23%, n = 135), and 33.4% (n = 196) were diagnosed with dementia or neurocognitive disorder owing to another aetiology. Applying all lecanemab eligibility criteria, 11 (4.3%) patients with dementia and two (1.5%) patients with MCI would have been eligible for treatment with this compound, whereas 13 dementia (5.1%) and 14 (10.4%) MCI patients met clinical inclusion criteria, but had no available amyloid status. Conclusions: Even in a memory clinic with a good infrastructure and sufficient facilities for dementia diagnostics, most patients do not meet the eligibility criteria for treatment with lecanemab.
- Open Access
- 11 March 2024
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 15, 1340498
COVID-19 restrictions promoted the newly occurring loneliness in older people – a prospective study in a memory clinic population
Introduction: A high burden and many negative outcomes for older people were associated with the COVID-19 pandemic. Social isolation and loneliness are prevalent health problems impacting well-being and quality of life and may have increased due to pandemic-related restrictions. Methods: This study investigate the influence of the COVID-19 pandemic on loneliness in people visiting a mem40ory clinic between March 2020 and September 2022. We conducted a prospective, single-center, questionnaire-based observational follow-up study to assess potential predictors of newly occurring, pandemic-related loneliness. Next to a newly developed COVID-19 questionnaire, a comprehensive neuropsychological test battery, the Neuropsychiatric Inventory and the Geriatric Depression Scale were used.Results: In total 426 people (mean age: 76.48 years, 12.9% cognitively intact, 33.1% diagnosed with Mild Cognitive Impairment, 49.8% diagnosed with dementia, and 4.2% diagnosed with depression) completed the COVID-19 questionnaire at baseline and 166 at follow-up. Newly occurring loneliness was indicated by 22.3% of baseline participants and by 24.1% of follow-up participants. Results of logistic regression analysis showed that living alone (OR 5.452) and having less contact with friends (OR 2.771) were most predictive of the occurrence of loneliness. The use of digital communication media as an alternative strategy for social interaction was lowest in dementia patients (6-13%).Discussion: In conclusion, personal contacts and a close friendship network appear to be more decisive to prevent loneliness in older people than does the use of digital communication media. However, promoting an intensified use of digital communication media may be useful to counteract loneliness, especially in dementia patients.
- 11 March 2024
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 15, 1340498
Open AccessCOVID-19 restrictions promoted the newly occurring loneliness in older people – a prospective study in a memory clinic population
Introduction: A high burden and many negative outcomes for older people were associated with the COVID-19 pandemic. Social isolation and loneliness are prevalent health problems impacting well-being and quality of life and may have increased due to pandemic-related restrictions. Methods: This study investigate the influence of the COVID-19 pandemic on loneliness in people visiting a mem40ory clinic between March 2020 and September 2022. We conducted a prospective, single-center, questionnaire-based observational follow-up study to assess potential predictors of newly occurring, pandemic-related loneliness. Next to a newly developed COVID-19 questionnaire, a comprehensive neuropsychological test battery, the Neuropsychiatric Inventory and the Geriatric Depression Scale were used.Results: In total 426 people (mean age: 76.48 years, 12.9% cognitively intact, 33.1% diagnosed with Mild Cognitive Impairment, 49.8% diagnosed with dementia, and 4.2% diagnosed with depression) completed the COVID-19 questionnaire at baseline and 166 at follow-up. Newly occurring loneliness was indicated by 22.3% of baseline participants and by 24.1% of follow-up participants. Results of logistic regression analysis showed that living alone (OR 5.452) and having less contact with friends (OR 2.771) were most predictive of the occurrence of loneliness. The use of digital communication media as an alternative strategy for social interaction was lowest in dementia patients (6-13%).Discussion: In conclusion, personal contacts and a close friendship network appear to be more decisive to prevent loneliness in older people than does the use of digital communication media. However, promoting an intensified use of digital communication media may be useful to counteract loneliness, especially in dementia patients.
- Open Access
- 29 October 2023
- Published by Springer Nature in Research Square
Impact of COVID-19 restrictions on newly occurring loneliness in older people – a prospective study in a memory clinic population
The COVID-19 pandemic was associated with high burden and numerous negative consequences for older people. Social isolation and loneliness are major and prevalent health problems impacting well-being and quality of life and may have increased due to pandemic-related restrictions. The present study investigate the impact of the COVID-19 pandemic on loneliness in people visiting a memory clinic between March 2020 and September 2022. We conducted a prospective, single-center, questionnaire-based observational follow-up study to assess potential predictors of newly occurring, pandemic-related loneliness. Next to a newly developed COVID-19 questionnaire, a comprehensive neuropsychological test battery, the Neuropsychiatric Inventory and the Geriatric Depression Scale were used. In total 426 people (mean age: 76.48 years, 12.9% cognitively intact, 33.1% diagnosed with Mild Cognitive Impairment, 49.8% diagnosed with dementia, and 4.2% diagnosed with depression) completed the COVID-19 questionnaire at baseline and 166 at follow-up. Newly occurring loneliness was indicated by 22.3% of baseline participants and by 24.1% of follow-up participants. Results of logistic regression analysis showed that living alone (OR 5.452) and having less contact with friends (OR 2.771) were most predictive of the occurrence of loneliness. The use of digital communication media as an alternative strategy for social interaction was lowest in dementia patients (6–13%). In conclusion, personal contacts and a close friendship network appear to be more decisive to prevent loneliness in older people than does the use of digital communication media. However, promoting an intensified use of digital communication media may be useful to counteract loneliness, especially in dementia patients.
- 29 October 2023
- Published by Springer Nature in Research Square
Open AccessImpact of COVID-19 restrictions on newly occurring loneliness in older people – a prospective study in a memory clinic population
The COVID-19 pandemic was associated with high burden and numerous negative consequences for older people. Social isolation and loneliness are major and prevalent health problems impacting well-being and quality of life and may have increased due to pandemic-related restrictions. The present study investigate the impact of the COVID-19 pandemic on loneliness in people visiting a memory clinic between March 2020 and September 2022. We conducted a prospective, single-center, questionnaire-based observational follow-up study to assess potential predictors of newly occurring, pandemic-related loneliness. Next to a newly developed COVID-19 questionnaire, a comprehensive neuropsychological test battery, the Neuropsychiatric Inventory and the Geriatric Depression Scale were used. In total 426 people (mean age: 76.48 years, 12.9% cognitively intact, 33.1% diagnosed with Mild Cognitive Impairment, 49.8% diagnosed with dementia, and 4.2% diagnosed with depression) completed the COVID-19 questionnaire at baseline and 166 at follow-up. Newly occurring loneliness was indicated by 22.3% of baseline participants and by 24.1% of follow-up participants. Results of logistic regression analysis showed that living alone (OR 5.452) and having less contact with friends (OR 2.771) were most predictive of the occurrence of loneliness. The use of digital communication media as an alternative strategy for social interaction was lowest in dementia patients (6–13%). In conclusion, personal contacts and a close friendship network appear to be more decisive to prevent loneliness in older people than does the use of digital communication media. However, promoting an intensified use of digital communication media may be useful to counteract loneliness, especially in dementia patients.